Eagle Pharmaceuticals

Eagle Pharmaceuticals is a publicly traded operating company, not a private investment fund. It is listed on NASDAQ under ticker EGRX and is structured as a specialty pharmaceutical company. The firm discovers, develops, and markets its own branded and generic injectable products directly to healthcare systems, rather than investing capital in external ventures.

The firm concentrates on injectable treatments for critical care and oncology in hospital settings. Its portfolio contains both complex generic injectables and new chemical entities (NCEs). Marketing names such as BYFAVO for procedural sedation and PEMFEXY for oncology reflect a focus on faster or safer administration in acute-care environments.

The firm's disclosed physical operations are all within the United States, with offices in New Jersey, Massachusetts, and Indiana. Its public materials cite a collaboration with Teva Pharmaceuticals on a bendamustine injection, but the geographical scope of that partnership is not detailed beyond North American distribution as shown on official packaging.

Business development and pipeline strategy are led by CEO Michael Graves and Chief Strategy Officer Daniel O'Connor, who also serves as Head of Corporate Development. Because Eagle is an operating company, investment decisions — such as acquiring or divesting a drug — are made by this leadership team and approved by a board of directors that includes medical scientist Luciana Borio.

Eagle does not invest in startups or venture-stage biotech. The company targets already approved or late-stage development assets that it can commercialize through optimized formulations for hospital use. Its product roster suggests a preference for acquiring mature, commercially available injectable drugs rather than funding preclinical discovery.